{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:09:23Z","timestamp":1791461363312,"version":"4.3.4"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0214727","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T17:34:07Z","timestamp":1554312847000},"page":"e0214727","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-4090","authenticated-orcid":true,"given":"Mitsuhide","family":"Naruse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-9678","authenticated-orcid":true,"given":"Ryuichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Arimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/hr.2014.20","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)","volume":"37","author":"K Shimamoto","year":"2014","journal-title":"Hypertens Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11154-014-9298-4","article-title":"Pharmacological treatment and therapeutic perspectives of metabolic syndrome","volume":"15","author":"S Lim","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"ref3","unstructured":"The Japanese Diabetes Society: Evidence-based practice guideline for the treatment for diabetes in Japan 2013. Available from: http:\/\/www.jds.or.jp\/modules\/en\/index.php?content_id=44<\/ext-link>."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1517\/14656566.2011.632367","article-title":"Telmisartan: just an antihypertensive agent? A literature review","volume":"12","author":"M Destro","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique Angiotensin II receptor antagonist with selective PPAR\u03b3-modulating activity","volume":"43","author":"SC Benson","year":"2004","journal-title":"Hypertension"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2169\/internalmedicine.49.3189","article-title":"Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients","volume":"49","author":"M Watanabe","year":"2010","journal-title":"Inter Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12325-012-0032-x","article-title":"Telmisartan at 80 mg\/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients","volume":"29","author":"H Mori","year":"2012","journal-title":"Adv Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.diabres.2008.07.003","article-title":"The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control","volume":"82","author":"A Yamana","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.diabres.2006.11.014","article-title":"Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients","volume":"77","author":"I Usui","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jash.2014.05.006","article-title":"All-Literature Investigation of Cardiovascular Evidence Group: A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients","volume":"8","author":"H Takagi","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"E287","DOI":"10.1152\/ajpendo.00440.2004","article-title":"PPAR gamma-mediated insulin sensitization: the importance of fat versus muscle","volume":"288","author":"U Kintscher","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/hr.2013.142","article-title":"A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction","volume":"37","author":"H Takagi","year":"2014","journal-title":"Hypertens Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/hr.2012.8","article-title":"Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study","volume":"35","author":"H Rakugi","year":"2012","journal-title":"Hypertens Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.amjhyper.2006.12.010","article-title":"TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation","volume":"20","author":"M Iwai","year":"2007","journal-title":"Am J Hypertension"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1463-1326.2011.01471.x","article-title":"Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats","volume":"13","author":"M Zhao","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"ref16","first-page":"94","article-title":"Usefulness of azilsartan (Azilva tablet) in patients with hypertension complicated by diabetes mellitus","volume":"20","author":"K Hiramitsu","year":"2013","journal-title":"J Blood Pressure"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"PA James","year":"2014","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and International Society of Hypertension","volume":"16","author":"MA Weber","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2261-14-148","article-title":"Effects of ACEI\/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies","volume":"14","author":"G Hao","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1291\/hypres.31.7","article-title":"Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetes with hypertension","volume":"31","author":"S Nakayama","year":"2008","journal-title":"Hypertens Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1507\/endocrj.EJ12-0326","article-title":"Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension","volume":"60","author":"T Arao","year":"2013","journal-title":"Endocr J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0214727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:12:43Z","timestamp":1589001163000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0214727"}},"subtitle":[],"editor":[{"given":"Doan TM","family":"Ngo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0214727","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]}}}